Blocking epigenetic “Swiss army knife” may be a new strategy for treating colorectal cancer
April 4, 2019
GRAND RAPIDS, Mich. (April 4, 2019) — A new study out today in Cancer Cell shows that blocking specific regions of a protein called UHRF1 switches on hundreds of cancer-fighting genes, impairing colorectal cancer cells’ ability to grow and spread throughout the body.
“Colorectal cancers are a growing public health problem, particularly in young people who haven’t yet reached the recommended age for regular screening,” said Scott Rothbart, Ph.D., an associate professor at Van Andel Research Institute (VARI) and co-corresponding author of the study. “UHRF1 has emerged in recent years as a key regulator of biological processes that drive colorectal cancer progression. This protein is akin to a molecular Swiss army knife, with many different parts that each have a different job. Revealing the parts that drive cancer progression could give us promising new ways to treat this disease.”
Colorectal cancers are the third leading cause of cancer-related death among both men and women in the U.S. While overall rates have been falling since the mid-1980s, the decrease is largely driven by routine screening in older adults. In people ages 20 to 39, rates are actually increasing — 1 to 2 percent a year between 1974 through 2013 for colon cancers and 3 percent per year between 1974 through 2013 for rectal cancers, according to a 2018 American Cancer Society report.
UHRF1 helps establish and maintain patterns of molecular tags on DNA, an epigenetic process known as methylation. These methylation patterns act like a switch that tells the body’s cellular machinery when specific genes should be turned on or off. In cancer cells, these patterns change, impeding the normal checks-and-balances on cell growth and allowing malignant cells to flourish and spread.
UHRF1 is a tantalizing new target that complements an emerging class of drugs called DNA methyltransferase inhibitors (DNMTis), which have shown exceptional promise for correcting methylation errors and treating cancer. However, many of the compounds developed to date have not been able to penetrate a sufficient number of tumor cells simultaneously to fully repair methylation and reactivate anti-cancer genes.
“Epigenetic therapies are a promising avenue for cancer treatment, but we need new drugs that better reverse abnormal DNA methylation in patients’ tumors with fewer side effects,” said Stephen Baylin, M.D., co-corresponding author of the study, Director’s Scholar at VARI and Virginia and D.K. Ludwig Professor for Cancer Research at Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University. “The strong anti-cancer effects that result when we block the regions of UHRF1 responsible for maintaining methylation are a critical step toward developing new, improved inhibitors for cancer treatment”.
Identification of these regions on UHRF1 also may help better identify colorectal cancer subtypes, improving physician’s ability to take a personalized approach to treatment. Using data provided by The Cancer Genome Atlas, a National Institutes of Health-led effort to molecularly map cancer, the team found a strong correlation between high levels of UHRF1 and more aggressive, tough-to-treat malignancies.
They now hope to translate their findings into actionable prognostic markers and, eventually, improved therapies that are more tolerable to patients and more effective at fighting cancer.
In addition to Rothbart and Baylin, Limin Xia, Ph.D., of Tongji Hospital also is co-corresponding author.
Other authors include Xiangqian Kong, Ph.D., Wenbing Xie, Ph.D., Stephen M. Brown, Yi Cai, Ph.D., Srinivasan Yegnasubramanian, M.D., Ph.D., Yong Tao, Ph.D., Ray-Whay Chiu Yen, M.S., Michael J. Topper, Cynthia A. Zahnow, Ph.D., and Hariharan Easwaran, M.Sc., Ph.D., of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Jie Chen, Kaichun Wu, M.D., Ph.D., Daiming Fan, M.D., Ph.D., and Yongzhan Nie, M.D., Ph.D., of State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University; and Rochelle Tiedemann, Ph.D., of Van Andel Research Institute. Kong, Chen and Xie are co-first authors. Chen also is affiliated with Tongji Hospital.
Research reported in this publication was supported by National Institute of Environmental Health Sciences award no. R01ES011858 (Baylin), National Institute of General Medical Sciences award no. R35GM124736 (Rothbart), National Natural Science Foundation of China award no. 81522031 (Xia) and no. 81772623 (Xia), National Key Research and Development Program of China award no. 2018YFC1312103 (Xia), and the American Cancer Society–Michigan Cancer Research Fund Postdoctoral Fellowship no. PF-16-245-01-DMC (Tiedemann). Research reported in this publication was also supported by The Hodson Trust (Baylin) and The Commonwealth Foundation (Baylin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the granting organizations.
ABOUT VAN ANDEL INSTITUTE
Van Andel Institute (VAI) is an independent nonprofit biomedical research and science education organization committed to improving the health and enhancing the lives of current and future generations. Established by Jay and Betty Van Andel in 1996 in Grand Rapids, Michigan, VAI has grown into a premier research and educational institution that supports the work of more than 400 scientists, educators and staff. Van Andel Research Institute (VARI), VAI’s research division, is dedicated to determining the epigenetic, genetic, molecular and cellular origins of cancer, Parkinson’s and other diseases and translating those findings into effective therapies. The Institute’s scientists work in onsite laboratories and participate in collaborative partnerships that span the globe. Learn more about Van Andel Institute at vai.org.
Beth Hinshaw Hall
Director of Communications & Marketing